COVID-19 in donation and transplant

Candel, Francisco Javier; Rey, Cándido Pardo; Torres‐González, Juan Ignacio; Fernández-Vega, Paula; Fragiel, Marcos; Oteo, David; Toro, Enrique Del; Vega-Bayol, Mónica; Outon, Cristina; Encabo, Marta; García-Marugán, Agustín; Resino, Sara; Parra, Dolores Aleixandre; Matesanz, Mayra; Gallegos, Francisco J. del Rio

doi:10.37201/req/s03.13.2022

Cited by 2 publications

(4 citation statements)

References 70 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, few studies have been published on the evaluation of the short-term outcomes in patients who received various transplant from SARS-CoV-2 positive donors. Although the data is very limited, they reported that the recipients receiving products from these donors does not adversely affect engraftment or survival ( 19 , 20 ). Despite these findings, the drafting of official guidelines of the national transplant center will be necessary for planning future cryopreserved ovarian tissue transplant in patient SARS-CoV-2 positive at the time of ovarian tissue retrieval.…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on ovarian tissue cryopreservation planning in the Bologna clinical center

Magnani

Vicenti²,

Fabbri³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

IntroductionTreatment of patients with COVID-19 has been a priority by competing with the treatment of any other disease due to limited hospital resources. The current pandemic situation has focused the attention of healthcare providers around the world away from all other non-emergency health problems, including oncofertility. The aim of the study was to evaluate the repercussions of the COVID-19 pandemic on the activity levels of ovarian tissue cryopreservation (OTC) in the our center.MethodsThe study analyzed the number of patients treated for OTC in our center during three periods: pre-pandemic period: March 2019-February 2020, pandemic period: March 2020-February 2021 and post-pandemic period: March 2021-February 2022.ResultsIn our center routine hospital operation was completely reorganized, allowing only urgent interventions. Continuing to urgently preserve fertility during the pandemic required rapid changes to our standard practices for the care of these vulnerable patients. Despite the modifications, there was no difference in the number of OTC performed among the periods analyzed. Similarly, the number of patients who did not perform OTC was the same over the three years analyzed.DiscussionDespite the local and national restructuring of care to conserve resources and protect the community, it is significant to continue offering fertility-sparing treatment to cancer patients. This emphasis on the importance of preserving fertility despite the pandemic further highlights the essential and urgent nature of this procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on ovarian tissue cryopreservation planning in the Bologna clinical center

Magnani

Vicenti²,

Fabbri³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…(kidney, liver, and heart) being transplantation a safe practice, with a low risk of transmission, regardless of the presence of symptoms at the time of procurement [8].…”

Section: Introductionmentioning

confidence: 99%

“…The impact on organ transplantation also varied with respect to organ type with preferential deferral of kidney transplant candidates who were stable on renal replacement therapy and/or had lower immunologic barriers to transplantation [ 4 ]. However, the majority of reports noted a decline in SOT in all organ types, with living donor programs generally suspended or curtailed in many sites [ 5 - 7 ], recent evidence has also shown that there is low risk for a transplant recipient to get infected from an already infected donor, especially in non-pulmonary organs (kidney, liver, and heart) being transplantation a safe practice, with a low risk of transmission, regardless of the presence of symptoms at the time of procurement [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…However, during the ongoing pandemic, from 2020 to 2021 mortality in SOT recipients has decreased from 20-25% to 8-10% as a result of increased and early availability of SARS-CoV-2 testing, adherence to non-pharmaceutical interventions (face covering, hand hygiene, physical distancing) to control spread of infection, development of novel treatments, and vaccination [ 10 ]. Nevertheless, transplant patients have less post-vaccination protection than the general population, this condition of lower protection should have implications for treatment [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies

Candel¹,

Salavert²,

Mingot³

et al. 2023

Rev Esp Quimioter

Self Cite

View full text Add to dashboard Cite

Recipients of solid organ transplants (SOT) are at higher risk of infection by SARS-CoV-2 virus especially due to chronic immunosuppression therapy and frequent multiple comorbid conditions. COVID-19 is a potentially life-threatening disease in SOT recipients, with an increased likelihood of progressing to severe disease, with the need of hospitalization, admission to the intensive care unit (ICU) and mechanical ventilatory support. This article presents an updated review of different aspects related to the outcome of COVID-19 in SOT recipients. In nvaccinated SOT recipients, COVID-19 is associated with a high mortality rate, in-patient care and ICU admission, and impaired graft function or rejection in severe disease. In vaccinated SOT recipients even after full vaccination, there is a reduction of the risk of mortality, but the course of COVID-19 may continue to be severe, influenced by the time from transplant, the net state of immunosuppression and having suffered graft rejection or dysfunction. SOT recipients develop lower immunity from mRNA vaccines with suboptimal response. Treatment with mAbs provides favorable outcomes in non-hospitalized SOT recipients at high risk for severe disease, with lower rates of hospitalization, emergency department visits, ICU care, progression to severe disease, and death. However, broad vaccination and therapeutic options are required, particularly in light of the tendency of the SARS-CoV-2 virus to adapt and evade both natural and vaccine-induced immunity.

show abstract

COVID-19 in donation and transplant

Cited by 2 publications

References 70 publications

Impact of the COVID-19 pandemic on ovarian tissue cryopreservation planning in the Bologna clinical center

Impact of the COVID-19 pandemic on ovarian tissue cryopreservation planning in the Bologna clinical center

Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies

Contact Info

Product

Resources

About